Syntekabio CEO Jung Jongseon Raises Rights Offering Participation from 30% to 60%

Jung Jongseon, CEO and largest shareholder of Syntekabio, has officially announced a significantly strengthened commitment to participate in the ongoing rights offering, compared to the initial plan.

Through the securities registration statement, CEO Jung previously stated, "I will participate in at least 30% of the shareholder allotment subscription." However, according to the report on the status of large shareholdings disclosed on December 2, he has decided to sell only about 40% of his allotted rights to new shares and retain the remaining 60%. This indicates his intention to exercise all of his remaining rights to new shares in the subscription.

Rights to new shares grant existing shareholders the right to purchase additional shares during a rights offering. By retaining rather than selling these rights, one can participate in the subscription. Therefore, holding 60% of the rights to new shares demonstrates a level of participation twice as high as the previously declared "at least 30% subscription."

This rights offering aims to raise funds for debt repayment, working capital, and the expansion of growth drivers such as AI drug development. It is being conducted through a shareholder allotment method, which gives priority subscription rights to existing shareholders.

As the global AI drug development market is rapidly growing, the company has recently been recognized for its technological capabilities, including the publication of 3bm-GPT research results in an international academic journal. The increased subscription participation by the largest shareholder is seen as a reflection of confidence in these technological advancements.

A Syntekabio representative stated, "The CEO, who is also the largest shareholder, decided to participate in the subscription at a higher level than initially planned, based on his confidence in the company's future growth potential," adding, "This reflects strong confidence in the company's AI drug development platform technology and its mid- to long-term vision."

The market is interpreting the increased subscription participation by the largest shareholder as a positive signal regarding management's business outlook, and there is growing interest in the results of the rights offering and future stock price trends.

This content was produced with the assistance of AI translation services.